Ahmet Dirican, MD
Geriatric Medicine · New Bedford, MANPI 1396723813
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Chiesi USA, Inc. accounts for 65.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $6,311 and has fallen 85.9% since, to $890 in 2025. Among geriatric medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $115.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$6K
- Otsuka America Pharmaceutical, Inc.$628
- AbbVie$478
- AstraZeneca$362
- Novo Nordisk$313
- Johnson & Johnson$311
- plus $1K from 12 others
Across 548 payments — averaging $3527.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$682K
- Eli Lilly$257K
- Astrazeneca UK Limited$245K
- AstraZeneca$191K
- Lexicon Pharmaceuticals, Inc.$117K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$111K
- plus $331K from 11 others
What the payments were for
- Travel & lodging$4,99555%
- Food & beverage$3,99644%
- Education$1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 5 | $5,924 |
| Otsuka America Pharmaceutical, Inc. | 6 | $628 |
| AbbVie(2 entities) | 15 | $478 |
| AstraZeneca | 9 | $362 |
| Novo Nordisk | 3 | $313 |
| Johnson & Johnson | 12 | $311 |
| Bayer | 3 | $244 |
| E.r. Squibb & Sons, L.L.C. | 3 | $228 |
| Sunovion Pharmaceuticals Inc. | 9 | $169 |
| Mylan Specialty L.p. | 2 | $144 |
| Astellas Pharma US Inc | 2 | $140 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Gilead | 1 | $32 |
| Radius Health, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| GSK | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,102 in reported general payments places this provider in the 95th percentile of 156 geriatric medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 421 | $205,667 |
| FarxigaDapagliflozin Propanediol | 268 | $162,292 |
| PromactaEltrombopag Olamine | 11 | $139,347 |
| OzempicSemaglutide | 128 | $135,799 |
| RexultiBrexpiprazole | 102 | $135,769 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $98,412 |
| LinzessLinaclotide | 144 | $97,361 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 24 | $97,118 |
| TrulicityDulaglutide | 79 | $73,107 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $60,312 |
| EliquisApixaban | 95 | $55,705 |
| CreonLipase/Protease/Amylase | 37 | $48,645 |
| Tresiba Flextouch U-100Insulin Degludec | 133 | $48,098 |
| RybelsusSemaglutide | 39 | $45,091 |
| Bydureon BciseExenatide Microspheres | 70 | $41,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Prezcobix, Invega Sustenna | $311 | $262,775445 claims |
| AbbVieLinzess, Creon, Vraylar | $478 | $186,443210 claims |
| Novo NordiskOzempic, Rybelsus | $313 | $180,890167 claims |
| AstraZenecaFarxiga | $362 | $162,292268 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $628 | $135,769102 claims |
| GileadBiktarvy, Descovy | $32 | $124,11436 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $12 | $112,797206 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $14 | $87,48093 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $27,20042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 geriatric medicine providers in Massachusetts.
Other geriatric medicine in New Bedford
- Irving RestituyoNew Bedford$9K
- Efrain TorresNew Bedford$882
- Medha MunshiBoston$64K
- W Vincent PerrelliWaltham$64K
- Asif MerchantChelmsford$6K
- Rocco RossiMashpee$6K
- Lilian MikaelConcord$5K
- Douglas KielBoston$5K
- Michael CantorBraintree$3K
- Lyanne Santana KhouryBrookline$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.